Skip to main content
Top
Gepubliceerd in: Bijblijven 6/2004

01-06-2004 | Artikelen

Botulinetoxine in de oogheelkunde

Auteur: Mw. Dr H. Smet

Gepubliceerd in: Bijblijven | Uitgave 6/2004

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Botulinetoxine werd intussen al enige tijd geleden door een oogarts geïntroduceerd als een mogelijk therapeuticum. Intussen heeft het een plaats verworven ter behandeling van blefarospasmen, hemifaciale spasmen, spastisch entropion, protectieve ptosis, strabisme, nystagmus. Er zijn twee producten beschikbaar op de markt. Ervaringen met Botox® worden besproken.
Literatuur
go back to reference Aoki R. A comparison of the safety margins of the botuline neurotoxin serotypes A, B and F in mice. Toxicon 2001;39:1815-20.CrossRefPubMed Aoki R. A comparison of the safety margins of the botuline neurotoxin serotypes A, B and F in mice. Toxicon 2001;39:1815-20.CrossRefPubMed
go back to reference Hambleton P, Moore AP. Botuline neurotoxins: origin, structure, molecular actions and antibodies. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:16-27. Hambleton P, Moore AP. Botuline neurotoxins: origin, structure, molecular actions and antibodies. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:16-27.
go back to reference Jankovic J. Extent of clinical problem, measurement of clinical resistance, development of antibodies, review of assay options. Toxins 1999;1(1):4. Jankovic J. Extent of clinical problem, measurement of clinical resistance, development of antibodies, review of assay options. Toxins 1999;1(1):4.
go back to reference Nusgens Z, Roggenkamper P. Comparison of two Botuline toxin preparations in the treatment of essential blepharospasm. Graefe's Arch Clin Exp Ophthalmol 1997;235:197-9.CrossRef Nusgens Z, Roggenkamper P. Comparison of two Botuline toxin preparations in the treatment of essential blepharospasm. Graefe's Arch Clin Exp Ophthalmol 1997;235:197-9.CrossRef
go back to reference Boghen DR, Lesser RL. Blepharospasm and hemifacial spasm. Corporate Library 2001;389(July):1-8. Boghen DR, Lesser RL. Blepharospasm and hemifacial spasm. Corporate Library 2001;389(July):1-8.
go back to reference Boghen DR, Lesser RL. Blepharospasm and hemifacial spasm. Curr Treat Options Neurol 2000;2(5):393-400.CrossRefPubMed Boghen DR, Lesser RL. Blepharospasm and hemifacial spasm. Curr Treat Options Neurol 2000;2(5):393-400.CrossRefPubMed
go back to reference Elston JS. Idiopathic Blepharospasm, hemifacial spasm and therapeutic ptosis induction. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:90-100. Elston JS. Idiopathic Blepharospasm, hemifacial spasm and therapeutic ptosis induction. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:90-100.
go back to reference Elston JS. The clinical use of botuline toxin. Seminar in ophthalmology 1998;3(4):249-260.CrossRef Elston JS. The clinical use of botuline toxin. Seminar in ophthalmology 1998;3(4):249-260.CrossRef
go back to reference Moore AP. Clinical aspects of treatment with botuline toxin. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:28-53 Moore AP. Clinical aspects of treatment with botuline toxin. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:28-53
go back to reference Osaka M, Keltner JL. Therapeutic review: Botuline A toxin in ophthalmology. Survey of Ophthalmol 1991;36(1):28-46.CrossRef Osaka M, Keltner JL. Therapeutic review: Botuline A toxin in ophthalmology. Survey of Ophthalmol 1991;36(1):28-46.CrossRef
go back to reference Jordan DR, Patrinely JR, Anderson RL, Thiese SM. (1989). Essential blepharospasm and related dystonias. Survey of Ophthalmology 1989;34(2):123-32.CrossRefPubMed Jordan DR, Patrinely JR, Anderson RL, Thiese SM. (1989). Essential blepharospasm and related dystonias. Survey of Ophthalmology 1989;34(2):123-32.CrossRefPubMed
go back to reference Tucha O, Naumann M, Berg D, et al. Quality of life in patients with blepharospasm. Acad Neurol Scand 2001;103(1):49-52.CrossRef Tucha O, Naumann M, Berg D, et al. Quality of life in patients with blepharospasm. Acad Neurol Scand 2001;103(1):49-52.CrossRef
go back to reference Wenzel T, Schneider P, Griengl H, et al. Psychiatric disorders in patients with blepharospasm: a reactive pattern. J Psychosom Res 2000;48(6):589-91.CrossRefPubMed Wenzel T, Schneider P, Griengl H, et al. Psychiatric disorders in patients with blepharospasm: a reactive pattern. J Psychosom Res 2000;48(6):589-91.CrossRefPubMed
go back to reference Aoki R. Immunologic properties of the botuline toxin serotypes. Toxins 1999;1:1-3. Aoki R. Immunologic properties of the botuline toxin serotypes. Toxins 1999;1:1-3.
go back to reference Adams GGW, Kirkness CM, Lee JP. Botuline toxin A induced protective ptosis. Eye 1987;1:603-8.PubMed Adams GGW, Kirkness CM, Lee JP. Botuline toxin A induced protective ptosis. Eye 1987;1:603-8.PubMed
go back to reference Fraco MFE, Fraco MD. An evaluation of the safety and efficacy of botuline toxin type A (Botox) when used to produce a protective ptosis. Clin. Exp. Ophthalmol. 2001;29(6):394-9.CrossRef Fraco MFE, Fraco MD. An evaluation of the safety and efficacy of botuline toxin type A (Botox) when used to produce a protective ptosis. Clin. Exp. Ophthalmol. 2001;29(6):394-9.CrossRef
go back to reference Ebner R. Botuline toxin type A in upper lid retraction of Graves’ opthalmopathy. J Clin Neurol Ophthalmol. 1993;13(4):258-61. Ebner R. Botuline toxin type A in upper lid retraction of Graves’ opthalmopathy. J Clin Neurol Ophthalmol. 1993;13(4):258-61.
go back to reference Kikkawa DO, Cruz RC, Christian WK, et al. Botuline A toxin injection for restrictive myopathy, thyroid related orbitopathy: effects on intraocular pressure. Am J Ophthalmol 2003;135(4):427-31.CrossRefPubMed Kikkawa DO, Cruz RC, Christian WK, et al. Botuline A toxin injection for restrictive myopathy, thyroid related orbitopathy: effects on intraocular pressure. Am J Ophthalmol 2003;135(4):427-31.CrossRefPubMed
go back to reference Lee JP. Strabismus and other ocular motility disorders. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:71-89. Lee JP. Strabismus and other ocular motility disorders. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:71-89.
go back to reference Lennerstrand G, Nordbo OA, Tian S, et al. Treatment of strabismus and nystagmus with botuline toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand 1998;76(1):21-7.CrossRef Lennerstrand G, Nordbo OA, Tian S, et al. Treatment of strabismus and nystagmus with botuline toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand 1998;76(1):21-7.CrossRef
go back to reference Lyons CJ, Vickers SF, Lee JP. Botuline toxin therapy in dysthyroid strabismus. Eye 1990;4(4):538-42.PubMed Lyons CJ, Vickers SF, Lee JP. Botuline toxin therapy in dysthyroid strabismus. Eye 1990;4(4):538-42.PubMed
go back to reference McNeer KW, Tucker MG, Spencer RF. Management of essential infantile esotropia with botuline toxin A: review and recommendations. J Pediatr Ophthalmol and Strab 2000;37(2):63-7. McNeer KW, Tucker MG, Spencer RF. Management of essential infantile esotropia with botuline toxin A: review and recommendations. J Pediatr Ophthalmol and Strab 2000;37(2):63-7.
Metagegevens
Titel
Botulinetoxine in de oogheelkunde
Auteur
Mw. Dr H. Smet
Publicatiedatum
01-06-2004
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Bijblijven / Uitgave 6/2004
Print ISSN: 0168-9428
Elektronisch ISSN: 1876-4916
DOI
https://doi.org/10.1007/BF03059785

Andere artikelen Uitgave 6/2004

Bijblijven 6/2004 Naar de uitgave

Artikelen

Het rode oog